NCT00730639 - A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies | Biotech Hunter

Enrollment

395

Participants

Timeline

Start Date

October 30, 2008

Primary Completion Date

February 4, 2013

Study Completion Date

December 22, 2020

Conditions

Metastatic Castration-resistant Prostrate CancerRenal Cell CarcinomaMetastatic MelanomaNon-small Cell Lung Cancer

Interventions

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response

BIOLOGICAL

BMS-936558 (MDX-1106)

Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response

Trial Locations (13)

10065

Memorial Sloan Kettering Nassau, New York

21231

Johns Hopkins University, Baltimore

28078

Carolina Biooncology Institute, Huntersville

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt-Ingram Cancer Ctr, Nashville

45219

Christ Hospital, Cincinnati

48109

University Of Michigan Cancer Center, Ann Arbor

85258

Pinnacle Oncology Hematology, Scottsdale

06520

Yale University School Of Medicine, New Haven

33612-9497

H. Lee Moffitt Cancer Center & Research Institute, Tampa

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston